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Mullany LK, Hanse EA, Romano A, Blomquist CH, Mason JI,
Delvoux B, Anttila C, Albrecht JH. Cyclin D1 regulates hepatic
estrogen and androgen metabolism. Am J Physiol Gastrointest Liver
Physiol 298: G884–G895, 2010. First published March 25, 2010;
doi:10.1152/ajpgi.00471.2009.—Cyclin D1 is a cell cycle control
protein that plays an important role in regenerating liver and many
types of cancer. Previous reports have shown that cyclin D1 can
directly enhance estrogen receptor activity and inhibit androgen re-
ceptor activity in a ligand-independent manner and thus may play an
important role in hormone-responsive malignancies. In this study, we
examine a distinct mechanism by which cyclin D1 regulates sex
steroid signaling, via altered metabolism of these hormones at the
tissue and cellular level. In male mouse liver, ectopic expression of
cyclin D1 regulated genes involved in the synthesis and degradation
of sex steroid hormones in a pattern that would predict increased
estrogen and decreased androgen levels. Indeed, hepatic expression of
cyclin D1 led to increased serum estradiol levels, increased estrogen-
responsive gene expression, and decreased androgen-responsive gene
expression. Cyclin D1 also regulated the activity of several key
enzymatic reactions in the liver, including increased oxidation of
testosterone to androstenedione and decreased conversion of estradiol
to estrone. Similar findings were seen in the setting of physiological
cyclin D1 expression in regenerating liver. Knockdown of cyclin D1
in HuH7 cells produced reciprocal changes in steroid metabolism
genes compared with cyclin D1 overexpression in mouse liver. In
conclusion, these studies establish a novel link between the cell cycle
machinery and sex steroid metabolism and provide a distinct mech-
anism by which cyclin D1 may regulate hormone signaling. Further-
more, these results suggest that increased cyclin D1 expression, which
occurs in liver regeneration and liver diseases, may contribute to the
feminization seen in these settings.
cyclin D1b; liver regeneration; steroid 5- reductase; 17-hydroxys-
teroid dehydrogenase; 3-hydroxysteroid dehydrogenase
IN MANY CIRCUMSTANCES, the actions of sex steroids are deter-
mined by their local synthesis and inactivation rather than the
circulating levels of these hormones (29). Biologically active
hormones are produced from circulating precursors such as
dehydroepiandrosterone (DHEA) and act in a paracrine or
intracrine manner. In addition, the level of these compounds is
controlled by inactivating enzymes that often act within the
tissue microenvironment (29). Although the enzymatic path-
ways that control sex steroid hormone production and inacti-
vation have been extensively studied, relatively little is known
about their regulation at the tissue level. This is an issue of
some importance given the significant role that estrogens and
androgens play in diverse processes including cell prolifera-
tion, differentiation, metabolism, and cancer. A better under-
standing of how key enzymes are regulated at the cellular and
tissue level may provide insight into new therapeutic targets for
diseases such as cancer.
Sex steroids potently promote the proliferation of some
types of cells. For example, activation of the androgen receptor
(AR) and estrogen receptor  (ER) in prostate and breast
epithelial cells, respectively, triggers the cell cycle machinery,
consisting of cyclin/cyclin-dependent kinase (cdk) complexes
(3, 13). A key target of both of these receptors is cyclin D1,
which is induced by mitogens during G1 phase and plays a
pivotal role in cell cycle progression. In many types of cancers,
aberrant expression of cyclin D1 contributes to uncontrolled
proliferation and other effects that underlie the malignant
phenotype (20, 25). In androgen-responsive prostate cancer
cells and estrogen-responsive breast cancer cells, blockade of
their respective receptors leads to decreased cyclin D1 expres-
sion and diminished proliferation (3, 13).
Interestingly, cyclin D1 appears to enhance ER activity and
inhibit AR activity, thereby producing potential positive and
negative feedback signals to these respective receptors. This
may occur through several potential mechanisms, including
direct binding to the receptors, inactivation of the retinoblas-
toma protein (Rb), and regulation of transcriptional coregula-
tors (3, 10, 20). However, the existing literature contains some
conflicting information regarding the underlying mechanisms,
and it is possible that cyclin D1 regulates the activity of these
receptors via additional pathways.
The liver plays an important role in the biotransformation of
steroid hormones. Men with advanced liver diseases can de-
velop a feminization syndrome with increased estradiol (E2)
and decreased androgen levels, and similar effects are seen
acutely after major liver resection (17, 18, 41). However, the
mechanisms that modulate hepatic sex steroid metabolism
under these circumstances have not been established. In addi-
tion to regulating sex steroid hormones, hepatocytes express
ER and AR and respond to estrogens and androgens (21). For
example, E2 has both proliferative and metabolic effects on
hepatocytes in culture and in vivo (4, 19, 22). E2 has been
shown to promote proliferation of male primary hepatocytes
and hepatocellular carcinoma (HCC) cells in culture (4, 19).
Studies have also suggested that increased estrogen levels may
correlate with an increased risk of HCC in men and postmeno-
pausal women (8, 40). Although increased serum androgen
levels have also been linked to HCC development, recent
studies indicate that altered metabolism in liver diseases and
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HCC can lead to conversion of androgens to estrogens with a
net “estrogenic” effect at the cellular and tissue level (7, 23).
Notably, HCC almost always occurs in cirrhotic livers, which
frequently display ongoing hepatocyte proliferation and in-
creased cyclin D1 expression (2, 32).
Although they rarely divide in normal adult liver, differen-
tiated hepatocytes readily enter the cell cycle in response to
liver injuries that diminish functional hepatic mass (15). Pre-
vious studies have shown that cyclin D1 plays an important
role in hepatocyte proliferation and is sufficient to promote cell
cycle progression in the absence of other stimuli (1, 34). As
part of an effort to define novel effects of this protein in the
liver (33), we have examined the regulation of enzymes that
control the synthesis and inactivation of sex steroid hormones
by cyclin D1. Our results indicate that cyclin D1 regulates key
enzymes involved in the metabolism of these compounds in a
manner that favors increased estrogen and decreased androgen
accumulation in the liver and in HCC cells. These studies
suggest that cyclin D1 significantly modulates sex steroid
metabolism at the cellular and tissue level and thus provides a
potential mechanism for the feminization syndrome seen in
males with advanced liver disease or major liver resection. In
addition, local regulation of hormone ligand levels by cyclin
D1 may help to explain its effects on ER and AR activity.
These findings offer further insight into the complex relation-
ship between sex steroids, cyclin D1, and cell cycle control in
liver diseases and cancer.
EXPERIMENTAL PROCEDURES
Adenoviruses. Adenoviruses encoding cyclin D1, cyclin D2, cyclin
D3, and -galactosidase were prepared as previously described (33).
Adenoviruses encoding human cyclin D1b and cyclin D1-KE were
constructed by Vector Biolabs (Philadelphia, PA) from plasmids
kindly provided by Erik S. Knudsen (Thomas Jefferson University,
Philadelphia, PA) and Philip W. Hinds (Tufts-New England Medical
Center, Boston, MA).
Animal procedures. All animal studies were approved by the
Institutional Animal Care and Use Committee and were completed
following National Institutes of Health guidelines. Eight-week-old
male BALB/c (Harlan Sprague Dawley) mice were injected with
7–9  109 plaque-forming units via tail vein injection of recombinant
adenovirus as previously described (34), and livers were harvested
after 24 h. Letrozole (Novartis) was suspended in ethanol and admin-
istered at a concentration of 20 g/animal at 24 and 2 h prior to
harvest as indicated. Ethanol was injected in other animals as a vehicle
control. A 70% partial hepatectomy (PH) followed by liver harvest at
42 h was performed as previously described (34).
Western blots. Protein isolated from liver tissue was used for
Western blot analysis as described previously (1, 34). Antibodies used
for Western blot include cyclin D1 (UBI, Temecula, CA), cdk1 (Santa
Cruz Biotechnology), and actin (Sigma). Cyclin D1b antibody was
kindly provided by Erik S. Knudsen.
BrdU labeling. Liver samples were fixed in 10% formalin, paraf-
finized, and sectioned. Samples were stained using the Mouse on
Mouse IgG (Vector Laboratories) and the anti- bromodeoxyuridine
(BrdU) primary antibody (GE Healthcare). Peroxidase was activated
by using the DAB kit (Vector Laboratories) and counterstain was
performed with hematoxylin (Sigma). Positive nuclei were counted
per 100 hepatocytes.
Quantification of mRNA by real-time RT-PCR. Total RNA from
each liver was isolated and quantified as previously described (35).
RNA (5 g) was treated with DNase I (DNA-free, Ambion) according
to the manufacturer’s instructions. cDNA was synthesized with a
TaqMan reverse transcriptase reagent kit (Applied Biosystems)
primed with oligo(dT). Primers specific for genes of interest were
previously published or designed using Primer Depot (primerdepot.
nci.nih.gov) and purchased from Integrated DNA Technologies. Se-
quences and references are provided in Supplementary Table S1. Real-
time PCR was performed using the Light Cycler DNA Master SYBR
Green I kit (Roche Applied Sciences). Primers were used at a concen-
tration of 0.5 M and MgCl2 at 2.4 mM. Samples were denatured for 10
min at 95°C and then 40 cycles of 95°C for 20 s, 60°C for 20 s, and 72°C
for 20 s. Results were normalized to GAPDH. The RT-PCR data for each
figure represent three to four samples, and a separate experiment using
different specimens provided similar results (data not shown).
Analysis of serum steroid levels. Blood samples were taken and
serum was prepared and frozen at80°C until assayed. Serum E2 was
measured according to the manufacturer’s instructions using an en-
zyme immunoassay kit from Cayman Chemical (Ann Arbor, MI).
Prior to measurement, serum was extracted with ether and reconsti-
tuted in EIA buffer according to the manufacturer’s directions.
Cell culture. HuH7 cells were purchased from Riken BioResource
Center (Japan) and routinely cultured in DMEM with 10% FBS. For
experiments, cells were seeded at a density of 400,000 cells per well
in six-well plates with 3 ml of phenol red-free MEM with 10%
charcoal-stripped FBS per well. Cells were cultured in the presence or
absence of DHEA or E2 as indicated in the figures.
Cyclin D1 siRNA. Small interfering RNA (siRNA) transfer into
HuH7 cells was administered using DharmaFECT4 (Thermo Scien-
tific) according to manufacturer’s instructions. Briefly, cells were
plated as described above and incubated overnight. The following
day, cells were treated with a 400-l reaction mixture containing 1
nM control siRNA [NonTargeting pool cat. no. D-001810-10-20
(Thermo Scientific Dharmacon)] or 1 nM cyclin D1 siRNA [On-
Target plus Smart Pool cat. no. L-003210-00]. After an overnight
incubation, fresh medium was added and the cells were cultured
overnight with DHEA, E2, or vehicle control. Two days after siRNA
treatment, protein lysates were prepared or total RNA was isolated as
described above.
Enzyme assays used to measure conversion of testosterone and
DHEA to androstenedione. Flash-frozen livers were homogenized in
a Dounce homogenizer at a concentration of 100 mg/ml in an ice-cold
buffer containing 20% (vol/vol) glycerol, 10 mM 2-mercaptoethanol
and 40 mM potassium phosphate, pH 7.0, and centrifuged at 1,000 g
for 10 min. The supernatants were stored at 4°C and used within 5 h.
Assays were optimized to be in the linear range of product formation
and performed as described previously (5). For 3-HSD assays using
DHEA as substrate (Fig. 3A), a 10-l aliquot of lysate was incubated
with 10-l reaction mixture containing 1.0 mM NAD and 2.0 M
3H-DHEA ([1,2,6,7-3H]dehydroepiandrosterone, 100 Ci/mmol, from
PerkinElmer Life Sciences, Boston, MA) in 0.08 M bicine, pH 9.0,
and incubated at 37°C for 30 min. Oxidation of testosterone to
androstenedione (17-HSDox enzyme activity) (Fig. 3B) was assayed
by using liver lysates diluted 1:10. Lysates (10 l) were combined
with 10-l reaction mixture containing 1.0 mM NAD and 2.0 M
3H-testosterone ([1,2,6,7-3H]testosterone, 95.0 Ci/mmol from Amer-
sham Pharmacia Biotech, Arlington Heights, IL) in 0.08 M bicine, pH
9.0, and incubated at 37°C for 6 min. The reaction products were
analyzed as previously described (5). The percent conversion of
substrate was calculated from [cpm product/cpm product  substrate] 
100 and converted to picomoles per milligram tissue per 6 or 30 min
as shown in Figs. 3, A and B. The data are presented as the mean of
two or three livers assayed in duplicate for each condition.
Enzyme assays used to measure aromatase, steroid sulfatase, and
17-HSD activities. Flash-frozen livers were homogenized in a
Dounce homogenizer in RIPA buffer (50 mM Tris·HCl, pH 7.4 1%
Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM
EDTA). Nondissolved cell remnants were removed through centrifu-
gation at 15,000 g and the supernatant was stored at 80°C. Protein
concentration was determined by using the BC Assay Protein Quan-
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titation Kit (Uptima, Interchim). A recently developed HPLC method
was used to measure the amounts of estrone (E1) or E2 in the reaction
mixtures (11, 12). Aromatase activity (Fig. 3C) was assayed by using
50–75 g protein lysate incubated with 1 mM NADPH and 9 nmol
androstenedione in 100 mM potassium phosphate buffer (pH 7.4) for
24 h at 37°C in a 500-l reaction. The conversion of E2 to E1
(17-HSD oxidative activity) (Fig. 3D) was carried out as described
(11, 12). Fifty to 75 g lysate was incubated with a 500-l reaction
mixture containing 5 mM NADP and 10 nmol E2 in 100 mM
potassium phosphate buffer (pH 7.4) for 24 h. The conversion of E1
to E2 (17-HSD reductive activity) (Fig. 3E) was assayed using
50–75 g liver lysate combined with 500-l reaction mixture con-
taining 2.6 mM NADP, 3.3 mM glucose-6-phosphate, 1 U glucose-
6-phosphate dehydrogenase, 3.3 mM magnesium chloride, and 10
nmol E1 in 100 mM potassium phosphate buffer (pH 7.4) for 24 h.
Steroid sulfatase (STS) activity was measured as E1 produced from
E1–1-sulfate (Fig. 3F), as previously described (12). In brief, a 750-l
reaction mixture containing 4 mM NADP, 25 mM sucrose, and 10
nmol E1–3-sulfate in PBS (pH 7.4) was incubated with 50–75 g
lysate for 24 h. For Fig. 3, C–F, three to four livers were assayed for
each condition.
Statistics. Statistical significance was defined as P  0.05 by the
Student’s t-test. In each study, three to five independent mice or cell
culture replicates were used.
RESULTS
Cyclin D1 regulates the expression of key sex steroid me-
tabolism genes in the liver. Cyclin D1 is not expressed in
normal male adult liver but is induced in proliferating hepato-
cytes following 70% PH or other liver injury (15). Previous
studies have shown that transient transduction of the liver with
an adenoviral vector expressing cyclin D1 leads to robust
hepatocyte proliferation within 24 h and marked liver growth
Table 1. Cyclin D1 regulates genes involved in estrogen and
androgen metabolism
Gene Symbol Gene Name Fold Change
Akr1c19 aldo-keto reductase family 1, member C19 14.49
Arsg arylsulfatase G 4.83
Cyp1a2 cytochrome P450, family 1, subfamily a,
polypeptide 2
3.07
Gsta3 glutathione S-transferase 3 10.05
Hsd3b2 hydroxy--5-steroid dehydrogenase, 3- and
steroid -isomerase 2
16.96
Hsd3b5 hydroxy--5-steroid dehydrogenase, 3- and
steroid -isomerase
71.91
Hsd17b6 hydroxysteroid (17) dehydrogenase 6 18.04
Hsd17b10 hydroxysteroid (17) dehydrogenase 10 3.32
Rdh16 Retinol dehydrogenase 16 17.94
Srd5a1 steroid 5 -reductase 1 19.79
Srd5a2l steroid 5 -reductase 2-like 2.04
Stard4 StAR-related lipid transfer (START)
domain containing 4
5.46
Stard5 StAR-related lipid transfer (START)
domain containing 5
3.19
Sts Steroid sulfatase 2
Ugt2b1 UDP glucuronosyltransferase 2 family 4.12
Ugt2b38 UDP glucuronosyltransferase 2 family,
polypeptide B38
2.33
Fig. 1. Cyclin D1 and D1b regulate the expression of tran-
scripts encoding key enzymes involved in androgen and
estrogen metabolism in the liver. A: Western blot analysis for
cyclin D1, cyclin D1b, cdk1, and actin using liver lysates
from normal male mice or from livers 1 day after transfection
with the indicated adenoviruses. T(hr), hours; Adv, Adeno-
virus. B: DNA synthesis as estimated by bromodeoxyuridine
(BrdU) immunohistochemistry of hepatocyte nuclei (ex-
pressed as BrdU-positive nuclei per 100 hepatocytes). Con,
control. C: RT-PCR for selected hydroxysteroid dehydroge-
nase (HSD) genes using RNA isolated from untreated normal
or transfected livers. D: RT-PCR for SRD5A1. E: RT-PCR
for CYP1A2. RT-PCR data were normalized to Gapdh and
expressed as relative change compared with untreated livers.
Results are means 	 SE of at least 3 independent mouse
livers performed in triplicate. (*P  0.05 in each figure).
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(1, 34). Intravenously injected recombinant adenoviruses pri-
marily target hepatocytes, and this technique has been used
extensively to study the effect of single-gene expression in the
liver. We have recently shown that at 1 day after transfection,
cyclin D1 regulates genes involved in diverse pathways in the
livers of male mice (33). Further evaluation of these results
unexpectedly revealed that cyclin D1 regulated a number of
transcripts involved in androgen and estrogen metabolism.
Table 1 shows selected genes involved in the metabolism of
sex steroid hormones that were modulated by cyclin D1 in the
liver on the microarray (33). In this analysis, cyclin D1 regu-
lated the expression of several key genes involved in steroid hormone
biosynthesis, including GSTA3, HSD3B2, HSD17B6,
HSD17B10, SRD5A1, StARD4, StARD5, and STS, and enzymes
that catalyze the inactivation of steroid hormones, such as
HSD3B5, AKR1C19, CYP1A2, UGT2B1, and UGT2B38. These
findings suggest that cyclin D1 may modulate the level of sex
steroid hormone ligands at the tissue level.
To confirm these effects, RT-PCR was performed for key
sex steroid metabolism genes by using RNA isolated from
male mouse livers harvested 1 day after cyclin D1 or control
transfection (Fig. 1). We also examined the effect of cyclin
D1b, a common polymorphism of cyclin D1, on the expression
of these transcripts. Cyclin D1b is a splice variant that pos-
sesses a distinct COOH terminus and is associated with an
increased risk of some cancers (28). Recent studies have
suggested that cyclin D1b may regulate ER and AR activity
differently than cyclin D1 (6, 42). Expression of the cyclin D1
variants was confirmed by Western blot using COOH-terminal
antibodies that specifically recognize each (Fig. 1A). Transfec-
tion of cyclin D1b induced hepatocyte proliferation (as mea-
sured by DNA synthesis) and expression of cell cycle proteins
(such as cdk1) in a manner similar to cyclin D1 (34). As is
shown in Fig. 1B, cyclins D1 and D1b regulated the expression
of several hydroxysteroid dehydrogenase (HSD) genes, which
catalyze the conversion of androgens and estrogens. Specifi-
cally, both downregulated the expression of 3-hydroxysteroid
dehydrogenase type 5 (HSD3B5) and 17-hydroxysteroid de-
hydrogenase type 2 (HSD17B2). In contrast, cyclin D1 inhib-
ited expression of the 3-hydroxysteroid dehydrogenase type 2
(HSD3B2) mRNA, whereas cyclin D1b induced this transcript.
Cyclins D1 and D1b each inhibited expression of the mRNA
encoding steroid 5 -reductase 1 (SRD5A1), which catalyzes
the conversion of testosterone to the more potent androgen
dihydrotestosterone (DHT) (Fig. 1C) (38). CYP1A2, which
metabolically inactivates estrogens, was inhibited by both
cyclin D1 variants (Fig. 1D). The results in Fig. 1 suggest that
cyclin D1 may regulate sex steroid metabolism enzymes in a
manner that would favor increased estrogen and decreased
androgen levels in the liver.
Cyclin D1 leads to elevated serum E2 levels and regulates
hepatic estrogen- and androgen-responsive genes in males.
We next examined whether the regulation of sex steroid me-
tabolism genes by cyclin D1 had a biological effect. At 1 day
after transfection with cyclin D1 or D1b, serum E2 levels were
significantly increased in the male mice (Fig. 2A). This sug-
gests that the increase in serum E2 seen after major liver
resection or in liver disease in males may be due in part to the
induction of cyclin D1 in these settings (17, 18, 41). We also
examined whether cyclin D1 regulated the expression of es-
trogen- and androgen-responsive genes in the liver. As is
shown in Fig. 2B, cyclins D1 and D1b led to markedly
increased expression of LCN2 and SOCS3 mRNA, which are
known to be induced by estrogen in the breast (39) and liver
(31), respectively. Conversely, cyclins D1 and D1b led to
decreased expression of CAR3 and MUP1 (Fig. 2C), which are
androgen-responsive genes in the liver (16). These results
suggest that cyclin D1 increases estrogenic and decreases
androgenic signaling in the liver.
Fig. 2. Liver-specific expression of cyclin D1 increases serum
estradiol (E2) levels and regulates estrogen- and androgen-
responsive gene expression. A: serum E2 was measured in
serum from untreated male mice or mice transfected with the
cyclin D1, cyclin D1b, or control vectors. B: RT-PCR for
estrogen-responsive genes LCN2 and SOCS3. C: RT-PCR for
hepatic androgen-responsive genes CAR3 and MUP1.
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Since E2 has been reported to induce hepatocyte prolifera-
tion in culture, we asked whether the increase in estrogen
levels played a role in the proliferative response induced by
hepatic cyclin D1 expression. To test this, we treated mice with
the aromatase inhibitor letrozole, which is used to suppress
estrogen synthesis in hormone-responsive breast cancer. As
shown in Fig. 3A, letrozole completely prevented the induction
of serum E2 levels by cyclin D1. However, letrozole did not
affect the induction of hepatocyte DNA synthesis or cdk1
expression (Fig. 3, B and C). Furthermore, suppression of the
increased E2 production by letrozole did not prevent the
downregulation of SRD5A1 or the androgen target gene MUP1
transcripts.(Fig. 4D). These data suggest that the increased E2
levels are not required for the induction of hepatocyte prolif-
eration and that cyclin D1 promotes proliferation via the
canonical Rb-E2F pathway. The data also suggest that cyclin
D1 regulates hepatic androgen metabolism via an estrogen-
independent mechanism.
Cyclin D1 regulates the activity of steroid metabolizing
enzymes. The data in Fig. 1 indicate that cyclin D1 significantly
modulates the expression of a number of key sex steroid
metabolism genes. However, enzyme activities may be regu-
lated distinctly from transcript levels. To examine this further,
we performed assays for key enzymatic reactions on extracts
from male mouse livers as outlined in Fig. 4. To investigate the
production of androstenedione by 3-HSD or 17-HSD activ-
ities, enzyme assays were performed using either testosterone
or DHEA as substrate. Cyclins D1 and D1b led to decreased
conversion of DHEA to androstenedione (Fig. 4A), indicating
a decrease in 3-HSD activity. In comparison, there was a
much higher basal rate of conversion of testosterone to andro-
stenedione by 17-HSD in normal liver, and this was signifi-
cantly increased by both cyclins D1 and D1b (Fig. 4B). This
suggests that cyclin D1 may shift testosterone utilization away
from androgen synthesis and toward androstenedione produc-
tion in the liver.
Aromatase activity, measured as the conversion of andro-
stenedione to E1, was present in normal male liver (Fig. 4C).
This activity was highly variable in livers transfected with
cyclin D1, and no statistically significant change was detected.
In livers transfected with cyclin D1b, aromatase activity was
significantly increased. In Fig. 4D, the conversion of E2 to the
less potent estrogen ligand E1 by 17-HSD was examined. As
was the case for the oxidation of testosterone to androstenedi-
one (Fig. 4B), there was a relatively high rate of conversion of
E2 into E1 in normal liver (Fig. 4D). Cyclin D1 decreased this
activity, suggesting that it may cause a relative increase in E2
content at the tissue level. On the other hand, cyclin D1b
triggered a higher rate of E2 to E1 conversion.
In contrast to the high level of activities of inactivating
17-HSDs in normal liver, there was a 10-fold lower basal
level of activity of 17-HSDs responsible for the conversion of
E1 to E2 in the liver samples (data not shown). To examine this
further, the net conversion between E2 and E1 was calculated
for the liver samples by examining the ratio of activating
(reducing) to inactivating (oxidizing) 17-HSD enzyme activ-
ities, as has been previously described (24, 27). Cyclin D1
caused a substantial increase in this ratio, whereas cyclin D1b
Fig. 3. The aromatase inhibitor letrozole prevents induction of E2 levels but does not affect cell cycle progression or expression of SRD5A1 and MUP1 in
response to cyclin D1. Mice were treated (Treat.) with letrozole as outlined in EXPERIMENTAL PROCEDURES and transfected with the cyclin D1 or control
adenoviruses as in Fig. 1. A: serum E2 levels. B: hepatocyte DNA synthesis as assessed by BrdU uptake. C: Western blot of cyclin D1 and cdk1. D: RT-PCR
for SRD5A1 and MUP1.
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had no significant effect (Fig. 4E). Finally, the activity of STS,
which converts sulfated estrogens into nonconjugated estro-
gens, was measured in livers expressing cyclins D1 or D1b. As
measured by E1 production from the inactive sulfated form
(E1–1-sulfate), there was a high level of STS activity in the
liver samples (Fig. 4F). STS activity was significantly in-
creased by cyclin D1b but not cyclin D1. Taken together, these
data confirm that cyclin D1 regulates several key enzymes that
favor local E2 production. Interestingly, cyclin D1b differen-
tially regulates some of these enzymes and may favor greater
production of E1 and lower production of E2 at the tissue level
than does cyclin D1. This may be an additional explanation for
the recently published finding that cyclin D1b does not regulate
ER activity similarly to cyclin D1 in breast cancer cells (6).
Effect of cyclins D2, D3, and D1-KE. We next examined
whether the closely related D-type cyclins (D2 and D3) had a
similar effect in our model and whether cdk4 activation was
required for the effect. Cyclin D1 regulates cell cycle progres-
sion via activation of cdk4, but it can regulate other cellular
effects, such as transcriptional regulation, through cdk-inde-
pendent mechanisms (10, 20). In Fig. 5, mice were transfected
with adenoviruses encoding cyclin D2, cyclin D3, or a mutant
cyclin D1 with a lysine to glutamine point mutation in the
cyclin box, called cyclin D1-KE. This mutant does not activate
cdk4 (26, 30) and did not promote DNA synthesis or cell cycle
gene expression at 1 day after transfection (E. A. Hanse and
J. H. Albrecht, unpublished data). The cyclins D2, D3, and
D1-KE increased serum E2 levels to a similar degree as
wild-type cyclin D1 (Fig. 5B). Furthermore, each of these
D-type cyclins regulated the expression of key sex steroid
metabolism mRNAs in a pattern similar to that seen after
cyclin D1 transfection (Fig. 5C). These data suggest that each
of the D-type cyclins can regulate aspects of steroid metabo-
lism in the liver and that the mechanism is independent of cdk4
activation or cell cycle progression.
Regulation of sex steroid metabolism in regenerating liver.
We next examined whether the physiological induction of
cyclin D1 following 70% PH was associated with changes in
sex steroid metabolism similar to that observed with cyclin D1
transfection. The level of cyclin D1 induction after PH is less
than that seen after adenoviral transfection (34). We examined
liver harvested 42 h after PH, at which time cyclin D1 is
Fig. 4. Androgen and estrogen-converting enzyme-specific activities are regulated by cyclins D1 and D1b. A: specific activities of 3-HSDs with
dehydroepiandrosterone (DHEA) as a substrate were measured in livers from untreated male mouse livers or livers expressing cyclin D1, cyclin D1b, or control
vector. B: specific activity measurements of 17-HSDs with testosterone as a substrate. C: aromatase activity was measured as the conversion of androstenedione
(A) to estrone (E1). D: activity measurements of 17-HSDs responsible for the oxidation of E2 into the less active E1. E: activities of 17-HSDs responsible
for the reduction of E1 to E2 and the oxidation of E2 to E1 were measured and expressed as activity ratios of activating (reducing) vs. inactivating (oxidizing)
17-HSDs. F: steroid sulfatase (STS) activities were measured as conversion of E1–1-sulfate (E1-S) to E1
.
*P  0.05 between livers transfected with the cyclin
D1 or D1b adenoviruses compared with untreated or control-transfected livers. Results are means 	 SE of at least 3 independent mouse livers performed in
duplicate.
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significantly induced (34). As was seen after cyclin D1 trans-
fection, PH led to decreased expression of CYP1A2, HSD3B5,
and SRD5A1 mRNA (Fig. 6A). PH similarly induced the
expression of estrogen-responsive genes LCN2 and SOCS3
and decreased expression of androgen-responsive CAR3 (Fig.
6B). As has been previously reported (9), PH stimulated an
increase in serum E2 (Fig. 6C). PH led to a decrease in the
conversion of DHEA to androstenedione by 3-HSD activity
(Fig. 6D) and an increase in testosterone to androstenedione
conversion by 17-HSD activity (Fig. 6E), similar to the
effects seen after cyclin D1 transduction. These data provide
insight into the mechanisms underlying the shift in sex steroid
metabolism after PH in males that favor increased estrogen and
decreased androgen levels. Taken together with the data in
Figs. 1–5, these results suggest that cyclin D1 expression in the
regenerating liver may play a role in the feminization syn-
drome seen after major liver resection in men.
Cyclin D1 regulates key sex steroid metabolism genes in
HuH7 cells. The regulation of sex steroid metabolism by cyclin
D1 in mouse liver led us to investigate whether it has similar
effects in the well-differentiated human HCC cell line HuH7.
Because these cells express a high level of cyclin D1, we used
a knockdown approach to study the role of this protein. As is
shown in Fig. 7A, cyclin D1 mRNA and protein expression was
almost completely ablated by its siRNA. In Fig. 7B, the
expression of sex steroid metabolism transcripts was analyzed
in the presence or absence of the steroid precursor DHEA.
Cyclin D1 knockdown led to increased CYP1A2 expression,
which correlates well with the inhibition of this mRNA by
cyclin D1 expression and PH in the liver (Figs. 1 and 6). The
genes encoding 3-HSD enzyme dehydrogenases differ be-
tween mice and humans; human 3-HSD types 1 and 2 are
steroidogenic dehydrogenases that catalyze the conversion of
DHEA to androstenedione and appear to be similar to the
mouse 3-HSD type 2 dehydrogenase (37), which was down-
regulated by cyclin D1 (Fig. 1). Inhibition of cyclin D1 led to
increased HSD3B1 expression in HuH7 cells (Fig. 7B) but did
not affect HSD3B2 (data not shown). This suggests that cyclin
D1 may regulate 3-HSD activity in human cells via modula-
tion of HSD3B1. HSD17B2 catalyzes the conversion of E2 to
the less potent estrogen E1 (37), and expression of this tran-
script was increased by knockdown of cyclin D1. Consistent
Fig. 5. Regulation of hepatic steroid metabolism by cyclins D2,
D3, and D1-KE. Mice were transfected as in Figs. 1–3 with
adenoviruses expressing cyclin D2, cyclin D3, or the KE
mutant of cyclin D1 and harvested at 1 day after transfection.
A: expression of the indicated transfected proteins by Western
blot. B: serum E2 levels. C: RT-PCR of the indicated sex
steroid metabolism mRNA.
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with the data in mouse liver (Figs. 1–6), these findings suggest
that cyclin D1 affects E2 and E1 levels via regulation of
HSD17B2.
Steroid 5-reductase 1 (SRD5A1) plays a key role in
androgen production, and its expression was induced by
DHEA (Fig. 7B). In the presence of DHEA, cyclin D1
knockdown significantly promoted SRD5A1 expression,
whereas this transcript is downregulated in cyclin D1-
transfected mouse liver (Fig. 1). Expression of the andro-
gen-responsive CAR3 gene was induced by cyclin D1
siRNA in the presence of DHEA but not in its absence. This
suggests that direct modulation of the AR by cyclin D1 does
not account for the regulation of CAR3 in the absence of
ligand. However, these data support the concept that in-
creased production of androgen (via induction of SRD5A1
and potentially other mechanisms) promotes CAR3 expres-
sion following cyclin D1 knockdown in the presence of
steroid precursor (DHEA).
DISCUSSION
In this study, we provide evidence for a novel interaction
between the cell cycle machinery and sex steroid signaling,
whereby cyclin D1 regulates key enzymes involved in the
synthesis and degradation of these hormones. Although previ-
ous studies have documented that cyclin D1 controls the
activity of ER and AR through direct binding or by modu-
lating transcriptional coregulators, the present experiments
suggest that this protein can also regulate the levels of their
respective ligands. We found that cyclin D1 affected several
different enzymes that play an important role in sex steroid
metabolism, suggesting that it may have a coordinated effect
on these pathways.
Abnormal regulation of sex steroid metabolism in the
setting of liver diseases or resection is a well-described
phenomenon, but the underlying mechanisms have not been
established. In men with cirrhosis, hypogonadism and alter-
ations in the hypothalamic-pituitary axis may explain some
of the features of feminization (40). However, these changes
would not likely account for the increased estrogen levels
seen in men and postmenopausal women that occur acutely
after major liver resection (17, 18, 41), nor the increased
levels seen in male mice after PH (Fig. 5C) (9). After major
hepatectomy, a large number of hepatocytes enter the cell
cycle as part of the regenerative response, and this is
accompanied by marked induction of cyclin D1 (15, 34).
Cyclin D1 expression is also elevated in patients with
cirrhosis due to ongoing hepatocyte proliferation that helps
to sustain functional liver mass (2, 15, 32). In this study, we
provide evidence that cyclin D1 may account for changes in
sex steroid metabolism as follows: 1) Cyclin D1 regulated
the expression of a number of genes involved in steroid
synthesis and degradation in a pattern that would predict
increased estrogen and decreased androgen production in
the liver. 2) Short-term cyclin D1 expression in the liver led
to increased estrogen levels similar to those seen after PH.
3) Cyclin D1 promoted expression of estrogen-responsive
genes and downregulated androgen-responsive genes in the
liver. 4) Cyclin D1 regulated the hepatic activity of key
enzymes involved in sex steroid synthesis in a manner that
favors increased estrogen and decreased androgen synthesis.
5) PH in mice led to similar changes in gene expression and
enzyme activity to those induced by cyclin D1. 6) Knock-
down of cyclin D1 expression in the well-differentiated
HCC line HuH7 had reciprocal effects on several key genes
compared with cyclin D1 transfection in the liver. Although
it is highly likely that the hormonal changes seen in the
setting of liver disease or PH are regulated by several
Fig. 6. Steroid-converting enzymes expres-
sion and activities in the liver and serum E2
levels are regulated in during liver regener-
ation. RNA was isolated from normal livers
or 42 h after partial hepatectomy (PH) and
used for RT-PCR of the indicated genes.
A: steroid-converting enzymes. B: androgen
and estrogen-responsive genes. C: serum E2
levels. D: specific activities of 3-HSD with
DHEA as a substrate. E: specific activity
measurements of 17-HSDs, with testoster-
one as a substrate.
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factors, the data presented here suggest that expression of
cyclin D1 in hepatocytes plays an important role.
A handful of prior studies have suggested a link between the
cell cycle machinery and sex steroid metabolism, although a
causative role has not been previously established. For exam-
ple, in the fetal baboon adrenal gland, cyclin D1 expression
decreases during gestation whereas 3-HSD expression in-
creases (14). Treatment of human ovarian cells with the anti-
proliferative agents TGF-1 and all-trans retinoic acid induces
HSD3B1 expression, suggesting that cell cycle inhibition pro-
motes its expression (36). The data presented here demonstrate
that cyclin D1 inhibits 3-HSD activity (Fig. 3) and down-
regulates the expression of key 3-HSD genes (HSD3B1 and
murine HSD3B2, Figs. 1 and 7). In addition, we found that
cyclin D1 modulated 17-HSD mRNA expression and activity
in a manner that favors increased E2 and decreased testoster-
one synthesis (Figs. 1 and 4). To our knowledge, no previous
studies have shown that SRD5A1 varies during the cell cycle,
and thus our finding that SRD5A1 was regulated by cyclin D1
in mouse liver and human cancer cells lines is of particular
interest.
Previous studies have shown that a central “repressor
domain” of cyclin D1 can inhibit AR function by direct
binding to the receptor and by recruiting histone deacety-
lases to repress transcription (3). Of note, this mechanism
has been established by using transfection systems to over-
express cyclin D1, and we are unaware of prior studies
looking at knockdown of endogenous cyclin D1 expression.
The data presented here suggest that cyclin D1 may inhibit
AR activity through an additional mechanism, by reducing
the availability of androgen ligands. Although we have not
successfully performed SRD5A1 Western blot or 5-
reductase enzyme assays (data not shown), data from mouse
liver and human HuH7 cells show that this gene is inhibited
by cyclin D1 expression (Figs. 1 and 6). The downregulation
of SRD5A1 by cyclin D1 does not require the induction of
E2 (Fig. 3) or the activation of cdk4 (Fig. 5). 5-Reductase
plays a pivotal role in androgen synthesis, and inhibitors of
this enzyme are used for therapy of androgen-responsive
prostate cancer. Interestingly, we found that SRD5A1 ex-
pression was negligible in cultured HuH7 cells but was
induced by DHEA, suggesting that its expression is depen-
dent on steroid ligands. In the presence of DHEA (but not in
its absence), cyclin D1 siRNA significantly increased the
expression of AR target gene CAR3 (Fig. 7). Thus modu-
lation of endogenous cyclin D1 levels per se was not
sufficient to regulate CAR3, but the combination of a steroid
precursor and knockdown of cyclin D1 induced this gene.
These data suggest that cyclin D1 may regulate AR activity,
in part, by modulating synthesis of androgens at the tissue
and cellular level.
In cell culture systems, cyclin D1 has also been shown to
regulate the activity of ER through at least two different
ligand-independent mechanisms (10, 20, 42). The data pre-
sented here provide evidence that cyclin D1 also regulates the
availability of E2, thereby providing an additional potential
mechanism by which it can activate ER. Further study will be
required to determine the relative contribution of each mech-
anism, which may vary between cell types, tissues, and exper-
imental systems. A better understanding of the functional
relationship between cyclin D1 and ER may aid the devel-
opment of additional therapies for estrogen-responsive malig-
nancies.
The basis for performing the present studies was the
unexpected finding that transient cyclin D1 expression in the
liver regulated the expression of a significant number of
genes involved in sex steroid metabolism (Table 1) (33). We
have not yet examined other potentially relevant enzymes
and sex steroids that may be affected by cyclin D1. For
Fig. 7. Cyclin D1 regulates sex steroid converting enzymes in HuH7 cells.
Cells were cultured in the presence of 10% charcoal-stripped FBS. Cells were
treated with cyclin D1 or control small interfering RNA (siRNA) 2 days prior
to harvest and cultured with 10 nM DHEA for the final 24 h as indicated.
A: Western blot analysis (top) and RT-PCR (bottom) of cyclin D1 expression.
B: RT-PCR for the indicated genes from cells cultured in the presence and
absence of DHEA as described above.
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example, cyclin D1 downregulated the StARD4 and
StARD5 mRNA on the gene array; these encode StAR lipid
transfer proteins that control a rate-limiting step in the
biogenesis of steroid hormones. Similarly, cyclin D1 inhib-
ited expression of GSTA3, which also plays an important
role in steroid hormone synthesis. Cyclin D1 also down-
regulated expression of transcripts encoding glucuronyl-
transferases (UGT2B1 and UGT2B38) involved in steroid
deactivation. Furthermore, many of these same enzymes are
involved in the synthesis of progesterone, which may also
be affected by cyclin D1 expression. Although these find-
ings require further study, they suggest that cyclin D1
significantly regulates these enzyme pathways.
Taken together, our data are consistent with the theme
that cyclin D1 regulates hepatic sex steroid synthesis and
degradation at several levels (Fig. 8). Further study is
required to determine the mechanism(s) by which these
changes occur, but the findings suggest cyclin D1 may
trigger a coordinated response to alter the bioavailability of
these ligands in tissues and cells. Relatively little is known
about the transcriptional and posttranscriptional mecha-
nisms that regulate key enzymes involved in steroid hor-
mone synthesis (37). Cyclin D1 is known to modulate gene
transcription through phosphorylation or direct binding to
transcription factors and coregulators (10) and thus could be
inducing a coordinated transcriptional response. Notably,
we found that the cyclin D1-KE mutant, which does not
activate cdk4 or promote cell cycle progression at the time
point studied, produced similar changes in serum E2 and sex
steroid metabolism transcript expression. Cdk4-independent
actions of cyclin D1 include transcriptional regulation and
modulation of certain metabolic functions (3, 10, 20). Cy-
clins D2 and D3 also induced serum estrogen levels and
regulated key metabolic genes, suggesting that a shared
domain may affect the response. The central “repressor
domain” of cyclin D1 (which is intact in cyclin D1-KE) is
highly homologous to the corresponding regions in cyclins
D2 and D3 (3, 13), and thus each of the D-type cyclins may
be affecting hormone metabolism through a transcriptional
mechanism. However, further investigation will be required
to determine the mechanisms by which cyclin D regulates
hormone metabolism in the liver.
In summary, the present studies indicate that cyclin D1
regulates sex steroid metabolism in the liver and in human
cancer cells. Our findings present a potential mechanism for
the increased estrogen and decreased androgen levels seen in
males in the setting of liver resection or diseases. Furthermore,
these data suggest that cyclin D1 may enhance ER activity
and inhibit AR activity, at least in part, by modulating andro-
gen and estrogen ligands at the tissue or cellular level. These
actions of cyclin D1 may be highly relevant to its role in
hormone-responsive tissues and cancer.
Fig. 8. Proposed model for the regulation of sex steroid metabolism by cyclin
D1. Enzymatic reactions that are increased or decreased are labeled in red and
blue, respectively. A: expression of cyclin D1 in the liver leads to diminished
3-HSD activity converting DHEA to androstenedione but increases the
oxidation of testosterone to androstenedione by 17-HSD. Inhibition of 5-
reductase further diminishes production of dihydrotestosterone (DHT) from
testosterone, with the net result being decreased androgen receptor (AR)
activation. Cyclin D1 promotes accumulation of E2 from E1 by increasing the
relative reduction/oxidation activity of 17-HSD enzymes converting these
compounds and by decreasing CYP1A2 expression that normally inactivates
E2. The net result is increased estrogen stimulation of estrogen receptor 
(ER). B: cyclin D1b produces several similar effects, except that it also
increases aromatase activity, favors conversion of E2 to E1 by 17-HSD, and
increases STS activity. This results in less E2 and more E1 production than that
induced by cyclin D1, and relatively less ER activation. C: knockdown of
cyclin D1 in human cancer cells induces 5-reductase (SRD5A1) expression,
increases DHT levels, and activates AR. Depletion of cyclin D1 also promotes
3-HSD type 1 (HSD3B1) and 17-HSD type 2 (HSD17B2) expression. The
induction of HSD17B2 leads to increased conversion of E2 to E1, resulting in
diminished ER activation. Cyclin D1 may regulate other key enzymes in
these cell lines that remain to be studied.
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